بسم الله الرحمن الرحيم

MONA MAGHRABY

شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم

MONA MAGHRABY

شبكة المعلومات الجامعية

التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات

يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار

MONA MAGHRABY

The potential protective effect of niclosamide in a model of experimentally-induced liver fibrosis in rats

A thesis submitted for partial fulfillment of Master Degree in Pharmaceutical Sciences

(Pharmacology and Toxicology)

By

Manar Mohamed Esmail

B.Pharm. Sc., Ain Shams University (2016)

Demonstrator of Pharmacology and Toxicology

Faculty of Pharmacy, Egyptian Russian University

Under the Supervision of:

Associate Professor Reem Nabil Abou EL-Naga

Associate Professor in Pharmacology and Toxicology Department,

Faculty of Pharmacy,

Ain Shams University

Dr. Noha Mohamed Saeed

Lecturer in Pharmacology and Toxicology Department,

Faculty of Pharmacy,

Egyptian Russian University

Dr. Haidy Effat Michel

Lecturer in Pharmacology and Toxicology Department,

Faculty of Pharmacy,

Ain Shams University

(2021)

بسم الله الرحمن الرحيم

" وَقُلْ رَبِّ زِدْنِي عِلْمًا "

صدق الله العظيم

سورة طه (الأية ١١٤)

Acknowledgment

First and foremost, praises and thanks to the God, the Almighty, for His showers of blessings throughout my research work to complete the research successfully.

I would like to express my deep and sincere gratitude to my research supervisor, ***Associate Professor Reem Nabil Abou EL-Naga****, Associate Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for giving me the opportunity to do research and providing invaluable guidance throughout this research. Her mentorship was paramount in providing the experience needed for completing this study.*

I owe a special word of thanks to my supervisor, ***Dr. Noha Mohammed Saeed****, Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, for her advice, motivation, supervision, efforts, valuable suggestions during the practical part and crucial contribution during the whole research process. It would not have been possible to write this thesis without her help.*

I would like to explicit my sincere thanks to my supervisor, ***Dr. Haidy Effat Michel*** *Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for her guidance, continuous support, valuable advices, motivation, immense*

knowledge and patience during the whole process. Her guidance helped me in all the time of research and writing up this thesis.

I owe a lot to my parents for their continuous support, spiritual guidance and unconditional love throughout my personal and academic life. They provided me with the best of everything and gave me the strength to chase my dreams. My brothers deserve my wholehearted thanks as they always stood by my side, guiding me, helping me and supporting me.

I am thankful to ***Prof. Dr. Adel Bakeer Kholoussy****, Professor of Pathology, Faculty of Veterinary Medicine, Cairo University, and his highly respected laboratory team for their invaluable contribution in histopathological examination part of this work.*

I would like to give everlasting thanks to my colleagues at the Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, especially ***Prof. Dr. Laila Ahmed Abdel-Aziz****, Head of the Department, for sharing their potentialities, truthful and illuminating views on a number of issues related to the study. It is difficult to overstate my deepest appreciation to* ***Prof. Dr. Ihab Mohamed Fetouh****, Dean of Faculty of Pharmacy, Egyptian Russian University.*

Manar Mohamed Esmail

Content **page**

List of abbreviations VII

List of tables XII

List of figures XIII

Abstract 1

Introduction 3

1. Cholestatic liver diseases and liver fibrosis 3

1.1. Background 3

1.2. Cholestatic liver diseases etiology and prevalence 4

1.3. Cholestatic liver diseases diagnosis 6

1.4. Cholestatic liver fibrosis pathogenesis 8

1.4.1. Bile acid accumulation 8

1.4.1.1. Direct 8

1.4.1.2. Indirect 9

1.4.2. Oxidative stress 9

1.4.3. Inflammation 10

1.4.4. Bile duct proliferation 15

1.4.5. NOTCH pathway 17

1.4.6. Wnt pathway 22

1.4.7. Cholestatic liver fibrosis 23

1.5. Experimental models for cholestatic liver fibrosis 25

1.5.1. Obstructive model (Bile duct ligation) 25

1.5.2. Autoimmune models 25

1.5.3. Xenobiotic models 28

1.6. Therapeutic approaches for cholestatic liver fibrosis 30

1.6.1. Ursodeoxycholic acid 30

1.6.2. Obetocholic acid 30

1.6.3. Fibroblast growth factor-19 mimetics 31

1.6.4. Transmembrane G-coupled receptor 5 31

2. Niclosamide 32

2.1. Background 32

2.2. Chemistry 33

2.3. Pharmacokinetics 35

2.4. Pharmacodynamics 37

2.5. Toxicity 41

2.6. Safety 42

Aim of the work 42

Materials and methods 45

1. Design of the work 45

2. Materials 50

2.1. Animals 50

2.2. Drugs 51

2.3. Chemicals 51

2.4. Buffers 57

2.5. Readymade Kits 59

2.6. Antibodies 72

3. Methods 74

3.1. Biomarkers for hepatotoxicity 74

3.1.1. Assessment of serum aspartate transaminase (Doumas and Briggs) 74

3.1.2. Assessment of serum alanine transaminase (Reitman and Frankel, 1957): 77

3.2. Biomarkers for cholestasis..... 79

3.2.1. Assessment of serum gamma-glutamyl transferase 79

3.2.2. Assessment of Alkaline phosphatase QuantiChrom™ Alkaline Phosphatase Assay Kit (DALP-250) 81

3.3. Assessment of Oxidative stress markers..... 83

3.3.1 Determination of serum levels of thiobarbituric acid reactive substances indicative to malondialdehyde content 83

3.3.2. Assessment of serum levels of Superoxide dismutase 88

3.3.3. Assessment of liver content of reduced glutathione 92

3.3. Assessment of inflammatory markers using enzyme linked immunosorbent assay..... 96

3.3.1. Assessment of Interleukin-6 96

3.3.2. Assessment of Tumor Necrosis Factor-alpha.....100

3.3.3. Assessment of liver nuclear factor- kappa B content 105

3.4. Assessment of protein in tissue homogenate (Kruger, 2002): 109

3.5. Assessment of NOTCH and Wnt signaling pathways by Western blot technique 111

3.6. Assessment of SOX9.....116

3.7. Detection of alpha-smooth muscle actin (α-SMA) and transforming growth factor-beta (TGF-β1) by Immunohistochemistry technique: 119

3.8. Assessment of hydroxyproline 121

3.9. Histopathological examination 124

3.10. Statistical analysis 125

Results 126

1. Hepatotoxicity and cholestasis biomarkers 126

2. Oxidative stress markers and antioxidant enzymes 132

3. Inflammatory markers 138

4. NOTCH signaling pathway.....143

4. Wnt signaling pathway 152

5. Fibrotic markers 157

7. Liver histopathological assessment 167

Discussion.....170

Summary and conclusion.....179

References.....186

Arabic summery ١

List of abbreviations

ADAM	A disintegrin and metalloproteinase
ALP	Alkaline phosphatase
ALT	Alanine transaminase
AMAs	Antimitochondrial antibodies
ANIT	α-naphthyl isothiocyanate
ANOVA	analysis of variance
AR-V7	Androgen receptor- splice variant 7
AST	Aspartate transaminase
ATP	Adenosine triphosphate
Bcl2	B-cell lymphoma 2
BDL	Bile duct ligation
BECs	Biliary epithelial cells
BHT	Butylated hydroxytoluene
BSA	Bovine serum albumin
CAT	Catalase
CBF1	C promoter-binding factor-1
CLF	Cholestatic liver fibrosis

CSL	CBF1, Suppressor of Hairless, Lag-1
CYPs	Cytochrome P450 enzymes
DDC	Diethoxycarbonyl-dihydrocollidine
DMSO	Dimethyl sulfoxide
DNPH	Dinitrophenyl-hydrazine
DRC	Ductal reactive cells
Dvl2	Dishevelled2
ECM	Extracellular matrix
Egr-1	Early growth response1
ELISA	Enzyme-linked immunosorbent assay
EMT	Epithelial–Mesenchymal transition
ERCP	Endoscopic radiologic cholangiopancreatography
ERK	Extracellular signal-regulated kinase
FGF-19	Fibroblast growth factor-19
FZD1	Frizzled1
GGT	Gamma-glutamyl transferase
GSH	Glutathione
GSH-Px	Glutathione peroxidase
HAT	Histone acetyltransferases